11/14/2024
4:50 PM | Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
3:33 PM | PERCEPTIVE ADVISORS LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
8:44 AM | Deep Track Capital, LP (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
8:35 AM | Avoro Capital Advisors LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/12/2024
9:34 AM | FMR LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/08/2024
3:53 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/28/2024
3:41 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
10/25/2024
3:28 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
1:10 PM | Deutsch Peter E. (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
10/22/2024
2:24 PM | BlackRock, Inc. (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
10/15/2024
5:10 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/02/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
10/01/2024
5:26 PM | Sloan Sheldon (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/01/2024
5:34 PM | Sloan Sheldon (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
3:04 PM | Burrows Scott L (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/07/2024
8:12 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 424B3 | |
08/07/2024
3:17 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/10/2024
8:48 AM | FMR LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
05/30/2024
3:33 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2024
6:40 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
3:08 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/29/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
04/25/2024
3:40 PM | Fairmount Funds Management LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13D/A | |
04/25/2024
3:55 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/23/2024
5:22 PM | Avoro Capital Advisors LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
04/18/2024
7:24 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
04/01/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
04/01/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
03/20/2024
6:14 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form PRE 14A | |
03/18/2024
7:31 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/11/2024
7:19 AM | FMR LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
03/01/2024
5:14 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 10-K/A | |
02/29/2024
4:06 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/29/2024
3:07 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/20/2024
8:21 PM | Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
Turtle Cameron (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
7:47 PM | Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
3:37 PM | EcoR1 Capital, LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
02/14/2024
8:08 AM | Avoro Capital Advisors LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
02/14/2024
7:56 AM | Deep Track Capital, LP (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
02/14/2024
6:02 AM | RTW INVESTMENTS, LP (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
02/13/2024
5:46 PM | BCLS II Equity Opportunities, LP (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
There is a little known company that is changing warfare (Ad) With geo - political instability around the world investors are flocking to defense contract stocks.
There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military. Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t |
02/13/2024
8:39 AM | Polar Capital Holdings Plc (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
02/09/2024
9:20 AM | FMR LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
02/08/2024
3:36 PM | INTEGRATED CORE STRATEGIES LLC (0001319244) (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
02/06/2024
8:37 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 424B3 | |
02/05/2024
4:25 PM | McKenna Mark C. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
02/05/2024
4:29 PM | McKenna Mark C. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2024
6:36 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/02/2024
7:23 PM | King-Jones Heidy (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
7:27 PM | Burrows Scott L (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
7:31 PM | Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
Turtle Cameron (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
3:26 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/29/2023
4:00 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Co-Invest L.P. (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Fairmount Healthcare Fund L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/29/2023
4:00 PM | Fairmount Funds Management LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13D/A | |
12/26/2023
8:56 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form D
Notice of Exempt Offering of Securities | |
12/22/2023
5:00 PM | Burrows Scott L (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/22/2023
4:00 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
12/22/2023
3:32 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
12/13/2023
2:50 PM | PERCEPTIVE ADVISORS LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
12/11/2023
4:41 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Co-Invest L.P. (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Fairmount Healthcare Fund L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/08/2023
7:45 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/30/2023
4:18 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 424B3 | |
11/29/2023
4:08 PM | Fairmount Funds Management LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13D/A | |
11/28/2023
6:33 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/27/2023
3:27 PM | Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
Stelzer Laurie (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
11/27/2023
3:32 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
11/27/2023
3:33 PM | Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
Stelzer Laurie (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/27/2023
3:36 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/22/2023
7:45 PM | Aeglea BioTherapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/20/2023
11:15 PM | Aeglea BioTherapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
